Abstract
MAHOGANY: Will it Establish Zanbrutinib, a Second-generation Bruton Tyrosine Kinase Inhibitor, as a Preferred Targeted Therapy for Relapsed/Refractory Follicular and Marginal Zone Lymphomas?
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have